A breast cancer drug developed by AstraZeneca has been approved in the European Union for the treatment of certain types of ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
In a phase 3 trial-based cost-effectiveness analysis for advanced breast cancer, treatment with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the second line rather than the first line ...
SAN ANTONIO — For patients with advanced hormone receptor-positive, HER2-negative breast cancer, health-related quality of life is the same whether they receive CDK4/6 inhibitors in the first or ...
On November 27, Nature published the results of an innovative breast cancer research project from the Netherlands. This study, the SONIA trial, showed that delaying and shortening the duration of a ...
Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- breast cancer, but many patients still eventually relapse and become ...
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR ...
CDK 4/6 inhibitors are a treatment for hormone receptorpositive (HR-positive), HER2-negative breast cancer that has spread to other parts of the body. They come as pills, and are often given with ...
Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results